It's a bit of a slow day for corporate news, but Canal+ continues to buy MultiChoice on a regular basis, with its shares still trading below the asking price and giving circulation more time. In international news, Novo Nordisk, Europe's most valuable company, continues to reap profits from its weight loss products Ozempic and Wegovy.
The Takeover Regulatory Commission said this on Thursday on French media giant Canal+. has now increased its stake in MultiChoice to around 42.5% following a series of transactions between April 25 and April 30, spending between R118.05 and R120 per share. Canal + has made an offer of R125 per share for MultiChoice, and the latter has previously made it clear that he would still face takeover hurdles even if Canal + tried to increase its control. Ta. MultiChoice also announced that he has been given permission to publish a circular regarding the proposal until June 4, whereas previously his deadline was May 7. MultiChoice was down about 0.6% on Wednesday, but is up about 48% year-to-date.
MTN Ghana, the third most profitable market for Africa's largest mobile operator; reported a 49% jump in profits to 1.1 billion Ghanaian cedis (approximately 1.5 billion Rand). in a high interest rate environment. Mobile subscribers increased 1.2% to 27.8 million, active data subscribers increased 15.3% to 16 million, and data revenue increased 60%. The group has also seen growth in voice and his MoMo service. Although core profit increased, margins felt some pressure due to a difficult background such as rising fuel prices.
South Africans need to gain knowledge if we want to build a prosperous future. News24 has been keeping the nation informed for 25 years and we are entering a new chapter of fearless journalism. Join our free subscription trial to unlock this story and a world of news designed to inform, empower and inspire.
